Prostate cancer
NICE rejects J&J’s prostate cancer drug Erleada in initial guidance
Richard Staines
Johnson & Johnson, market access, NICE, Prostate cancer
0 Comment
Novartis’ radioligand therapy meets phase 3 prostate cancer trial target
Richard Staines
Advanced Accelerator Applications, Endocyte, Oncology, Prostate cancer
0 Comment
NICE says no to AZ’s Lynparza for prostate cancer
Phil Taylor
AstraZeneca, HEOR, Lynparza, NHS, NICE, Oncology, PARP inhibitor, Prostate cancer, UK
0 Comment
Oncology/ Patients/ Views & Analysis/ Views & Analysis/ Views and analysis
Sharing experiences to level the healthcare playing field
Amanda Barrell
BAME, clinical trials, diversity and inclusion, patient insights, Prostate cancer
0 Comment
Valirx eyes partnerships as first VAL201 study hits the mark
Phil Taylor
clinical trial, Oncology, Prostate cancer, Valirx
0 Comment
EU regulators back uses for AZ’s Lynparza in prostate and ovarian cancer
Richard Staines
AstraZeneca, cancer, ovarian cancer, Prostate cancer
0 Comment
News/ News/ News/ Oncology/ R&D
Poseida Therapeutics aims for $115m stock market launch to fund CAR-T R&D
Richard Staines
cancer, CAR T, Funding, IPO, multiple myeloma, Poseida Therapeutics, Prostate cancer
0 Comment